Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 276 | 44 | 227 |
| Samples | 259 | 42 | 214 |
| Peptides | 197 | 30 | 170 |
Function
ACVR2B · Activin A receptor type 2B
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000352511 | Q13705 | 276 | 197 |
Gene Properties
Recurrent Mutations
All 197 amino-acid changes on canonical ENST00000352511 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ACVR2B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ACVR2B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 19/612 3% |
| Colorectal Carcinoma | 7/143 5% | 46/3239 1% |
| Melanoma | 1/210 0% | 24/1899 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Neuroendocrine Tumour | 2/154 1% | 5/577 1% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 7/1390 0% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Gastric Carcinoma | 1/74 1% | 15/1809 1% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Non-Cancerous | 0/104 0% | 7/830 1% |
| Other Solid Cancers | 0/94 0% | 11/1515 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 14/2550 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 3/810 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 7/1592 0% |
| Ovarian Carcinoma | 0/109 0% | 6/998 1% |
| Hepatocellular Carcinoma | 0/46 0% | 12/2210 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Glioma | 0/52 0% | 10/2127 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Esophageal Carcinoma | 2/23 9% | 0/769 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Head and Neck Carcinoma | 1/85 1% | 2/1574 0% |
| B-Lymphoblastic Leukemia | 3/55 5% | 1/2640 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
Mutation Distribution
Where ACVR2B is mutated · all tissues, split by cell line vs tissue
How many mutations in ACVR2B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 276 mutations in ACVR2B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|